Bone Density Changes During Cancer Immunotherapy
Part of Cancer, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study tracks how a type of cancer treatment called anti-PD-1 immunotherapy affects bone strength over time. Researchers want to understand whether this treatment causes bone density loss and help develop ways to protect bones during cancer care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Starting or within 4 weeks of beginning anti-PD-1 immunotherapy (a type of immune-boosting cancer drug) approved by the FDA
- Cancer that is not metastatic (spread to other parts of the body)
- Life expectancy of at least 12 months according to your doctor
- No recent bone fractures in the pelvis, hips, thighs, or spine
- Able to lie flat still for 20-25 minutes for bone density imaging (a painless scan)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at bone complications in women who have finished treatment with denosumab (a bone-strengthening drug) and aromatase inhibitors (hormone therapy for breast cancer). It aims to learn more about what happens to bones after stopping these medications, which may help guide future care.
This study looks at how the natural aging of the body might affect how well bone-strengthening medications work for osteoporosis. If you are about to start one of these medications, the study will track your bone density over time to see how your response may differ based on your 'biological age.'
This study looks at how certain hormone treatments for prostate cancer might affect bone strength over time. It aims to help doctors understand how to protect bones in men with prostate cancer that has spread.
This study uses a CT scan to estimate how strong a cancer-affected bone area is, helping doctors evaluate fracture risk and bone management. It is aimed at adults with bone lesions from several common cancer types.
This study tracks bone health in breast cancer patients receiving hormone-blocking therapy (aromatase inhibitors, GnRH analogs, or tamoxifen). It aims to understand how these treatments affect bone mineral density.
This study looks at whether your blood vitamin D level is linked to hormone-related side effects caused by immune checkpoint cancer drugs. It may help doctors better predict who is at risk and how to monitor patients during treatment.
Hear when a new Breast Cancer (Triple Negative Breast Cancer (TNBC)) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.